DDInter1220 DDInter1376
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Meperidine
Milnacipran {u} (Compound) binds {v} (Gene) SLC6A4
Milnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Milnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Milnacipran {u} (Compound) causes {v} (Side Effect) Migraine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Milnacipran (Compound) resembles Levomilnacipran (Compound)
Milnacipran (Compound) resembles Meperidine (Compound)
Milnacipran (Compound) binds SLC6A4 (Gene)
Milnacipran (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Milnacipran (Compound) downregulates GJA1 (Gene)
Milnacipran (Compound) causes Migraine (Side Effect)
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Milnacipran may lead to a major life threatening interaction when taken with Phentermine
Milnacipran may lead to a major life threatening interaction when taken with Teriflunomide